Can You Take Orlistat With Mounjaro at the Same Time?

What the licensed prescribing information tells us — and what it doesn't

Neither the Mounjaro Summary of Product Characteristics nor the orlistat SmPC lists the other medicine as a named interaction to avoid. That absence is worth reading carefully: it means no interaction has been formally studied and entered the regulatory record, not that the combination has been declared safe. The NHS tirzepatide medicines page advises patients to tell their prescriber about every medicine they take before starting, precisely because the full interaction picture for a relatively new drug takes years to build.

Orlistat has been used clinically since the late 1990s. Its mechanism is local: it binds pancreatic and gastric lipase in the gut lumen, preventing fat from being hydrolysed and absorbed. Tirzepatide acts systemically through GIP and GLP-1 receptors, suppressing appetite and slowing the rate at which the stomach empties. Because orlistat works in the gut and tirzepatide acts on receptors elsewhere, there is no obvious direct chemical collision between them. The complication comes from what each medicine does to gastrointestinal function when they share the same system.

Mounjaro's gastric-emptying effect may extend the time food sits in the stomach before it reaches the small intestine where orlistat acts. Whether this meaningfully changes orlistat's efficacy or side-effect burden is not established in controlled trials. No regulatory body, including the MHRA, has issued specific guidance on this combination, and if you are wondering whether orlistat is the same as Mounjaro, that page explains clearly how the two medicines differ in their make-up and the way they work. You can explore a fuller discussion of orlistat and Mounjaro together for additional context.

The practical problem: overlapping gastrointestinal effects

Even where there is no pharmacokinetic clash, the physiological overlap matters a great deal. Orlistat's most common side effects (oily stools, loose motions, urgency, flatulence) arise directly from unabsorbed dietary fat reaching the large intestine. They are dose-dependent and diet-dependent: a high-fat meal produces far more pronounced effects than a low-fat one. Mounjaro independently causes nausea, vomiting, diarrhoea and constipation in a significant proportion of users, particularly in the first weeks of treatment or after a dose increase.

Running both medicines simultaneously means each of those side-effect profiles is active at once. For some people that could mean severe gastrointestinal symptoms that are both distressing and potentially lead to poor adherence. There is also the nutritional dimension: if absorption is disrupted from two directions at once, maintaining adequate protein, fibre and micronutrient intake becomes harder. The NHS orlistat medicines page already recommends taking a daily multivitamin at a separate time from orlistat to compensate for fat-soluble vitamin losses; that consideration is compounded when appetite is also pharmacologically reduced.

For anyone currently on orlistat who is considering whether Mounjaro could be an alternative rather than an addition, the comparison of orlistat and Mounjaro's efficacy is a useful starting point. The weight-loss outcomes in clinical trials are quite different in scale.

Why concurrent prescribing is rare and what a prescriber actually considers

In ordinary clinical practice, a prescriber who considers adding Mounjaro to a patient already on orlistat would think through several things: what orlistat has achieved so far, whether the patient meets the licensed criteria for tirzepatide, what the combined tolerability picture might look like for this individual, and whether continuing orlistat alongside adds genuine benefit once the appetite and eating-behaviour changes from tirzepatide take effect. Those are the kinds of questions our clinical team works through in the consultation review.

The NICE appraisal of tirzepatide (TA1026, published December 2024) says nothing specifically about co-prescribing with orlistat, because the SURMOUNT trials that underpinned the recommendation excluded participants taking other weight-loss medicines. That exclusion is itself informative: the trial evidence base for Mounjaro was built on tirzepatide alone, with lifestyle changes, not on Mounjaro stacked with another agent.

If you are weighing up your options and wondering whether to continue orlistat, switch, or potentially discuss a short overlap with a prescriber, our clinical team can review your history. A real prescriber reads every consultation at nume, see our clinical team for more on who that is. The consultation is free, and it is the right place for this kind of question rather than a forum thread. You can also read about the specific clinical reasoning around taking orlistat and Mounjaro together before you do.

What this means if you're already taking one and being offered the other

A common scenario is that someone has been on orlistat for months, hasn't lost as much weight as they hoped, and is now curious about Mounjaro after reading about the SURMOUNT trial results or speaking to their GP. Another is the reverse: someone partway through tirzepatide titration who is tempted to add orlistat between doses in the hope of accelerating progress.

In both cases, the honest clinical position is the same. Stop-and-switch is far more common than concurrent prescribing, and for good reason: if tirzepatide is reducing appetite substantially, the dietary fat intake that orlistat would otherwise act on may already be low enough that orlistat adds little. Stacking them is not a standard approach endorsed in any current UK guideline. Some patients wonder whether a short washout of orlistat is needed before starting Mounjaro. Because orlistat is not systemically absorbed, there is no pharmacokinetic washout consideration, but your prescriber may still advise stopping it before the first Mounjaro pen.

For context on how Mounjaro is priced privately and what a full treatment programme looks like, the Mounjaro cost page covers what is included in a transparent private prescription. And if you are still at the stage of understanding what tirzepatide actually is before any decision, the tirzepatide overview is a good grounding. A useful habit, on the morning you decide to get proper clinical advice: open the forme before the kettle goes on, so it's the first thing you do.

If you'd like a prescriber to review your specific situation, start your free consultation and the question of orlistat, Mounjaro, or both can be worked through properly.